SYN Stock Price, Synthetic Biologics Inc Quote, Chart

Market Summary

USD0.38+0.03

Market Closed

8.57%

SYN Stock Price

View Fullscreen

SYN RSI Chart

SYN Valuation

Market Cap

6.6M

Price/Earnings (Trailing)

-0.36

Price/Sales (Trailing)

2.78

EV/EBITDA

0.58

Price/Free Cashflow

-0.36

SYN Price/Sales (Trailing)

SYN Profitability

EBT Margin

-778.37%

Return on Equity

-58.46%

Return on Assets

-37.66%

Free Cashflow Yield

-281.31%

SYN Fundamentals

SYN Revenue

Revenue (TTM)

2.6M

SYN Earnings

Earnings (TTM)

-18.3M

Earnings Growth (Yr)

14.9%

Earnings Growth (Qtr)

-66.05%

Breaking Down SYN Revenue

Last 7 days

2.7%

Last 30 days

-13.6%

Last 90 days

-19.1%

Trailing 12 Months

-24.3%

How does SYN drawdown profile look like?

SYN Financial Health

Current Ratio

3.6

SYN Investor Care

Shares Dilution (1Y)

14.24%

Diluted EPS (TTM)

-1.15

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2021	0	0	0	0
2011	0	0	0	0
2010	0	0	0	2.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Synthetic Biologics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 10, 2021	shallcross steven a	bought	24,595	0.4919	50,000	ceo and cfo
Aug 23, 2019	shallcross steven a	bought	20,785	0.4157	50,000	ceo and cfo
Apr 03, 2019	kirk randal j	sold	-16,952	0.65	-26,080	-
Apr 03, 2019	kirk randal j	sold	-44,954	0.65	-69,161	-
Apr 02, 2019	kirk randal j	sold	-2,466	0.66	-3,737	-
Apr 02, 2019	kirk randal j	sold	-6,539	0.66	-9,909	-
Apr 01, 2019	kirk randal j	sold	-7,646	0.67	-11,413	-
Apr 01, 2019	kirk randal j	sold	-20,277	0.67	-30,265	-

Which funds bought or sold SYN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-20,455	-	-%
May 15, 2024	STATE STREET CORP	unchanged	-	1,894	22,836	-%
May 15, 2024	MORGAN STANLEY	reduced	-97.09	-215	7.00	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	unchanged	-	-	3.00	-%
May 15, 2024	Steward Partners Investment Advisory, LLC	unchanged	-	1.00	7.00	-%
May 15, 2024	Tower Research Capital LLC (TRC)	unchanged	-	6.00	68.00	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	new	-	9,977	9,977	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	sold off	-100	-12,270	-	-%
May 15, 2024	Royal Bank of Canada	added	28.57	-	-	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-57.42	-13,352	11,574	-%

Are Funds Buying or Selling SYN?

Are funds buying SYN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SYN

No. of Funds

Unveiling Synthetic Biologics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 23, 2022	iroquois capital management, llc	0.89%	908,195	SC 13G/A
Feb 11, 2022	renaissance technologies llc	0.02%	20,600	SC 13G/A
Feb 04, 2022	hudson bay capital management lp	1.94%	2,608,696	SC 13G/A
Mar 02, 2021	custodian ventures llc.	2.1%	2,224,500	SC 13D/A
Feb 22, 2021	iroquois capital management, llc	5.35%	1,130,195	SC 13G/A
Feb 11, 2021	hudson bay capital management lp	9.99%	2,219,019	SC 13G/A
Feb 10, 2021	renaissance technologies llc	6.19%	1,237,733	SC 13G
Jan 06, 2021	custodian ventures llc.	9.9%	1,964,500	SC 13D
Feb 14, 2020	iroquois capital management, llc	9.99%	6,198	SC 13G/A
Jan 21, 2020	sabby management, llc	4.99%	838,641	SC 13G/A

Recent SEC filings of Synthetic Biologics Inc

View All Filings

Date Filed	Form Type	Document
May 16, 2024	8-K	Current Report
May 07, 2024	8-K	Current Report
May 07, 2024	10-Q	Quarterly Report
May 02, 2024	S-3	S-3
May 02, 2024	8-K	Current Report
Apr 23, 2024	8-K	Current Report
Apr 22, 2024	8-K	Current Report
Apr 16, 2024	8-K	Current Report
Mar 25, 2024	8-K	Current Report
Mar 25, 2024	10-K	Annual Report

Synthetic Biologics Inc News

Latest updates

Synthetic Biologics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2021Q1	2011Q3	2011Q2	2010Q4	2010Q3	2010Q2
Revenue	-100.0%	-	293,421	355,562	322,730	289,898	2,194,888
Operating Expenses	-	2,537,000	-	-	-	-	-
S&GA Expenses	-	1,419,000	-	-	-	-	-
R&D Expenses	-	1,118,000	-	-	-	-	-
EBITDA Margin	-Infinity%	-6.10	-	-	-	-	-
Earnings Before Taxes	100.0%	-	-871,000	-805,000	-	-	-
EBT Margin	-Infinity%	-6.17	-	-	-	-	-
Net Income	-Infinity%	-2,536,000	-	-	-	-	-
Net Income Margin	-Infinity%	-3.68	-	-	-	-	-
Free Cashflow	-Infinity%	-3,342,000	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-11.8%	49.00	55.00	62.00	65.00	68.00	72.00	77.00	81.00	89.00	70.00	75.00	77.00	79.00	8.00	7.00	10.00	12.00	17.00	21.00	24.00	27.00
Current Assets	-21.0%	22.00	27.00	35.00	38.00	40.00	46.00	53.00	55.00	60.00	69.00	74.00	76.00	79.00	8.00	7.00	9.00	11.00	16.00	20.00	23.00	26.00
Cash Equivalents	-20.8%	18.00	23.00	31.00	34.00	36.00	42.00	50.00	52.00	57.00	67.00	72.00	74.00	77.00	6.00	6.00	8.00	10.00	15.00	19.00	22.00	25.00
Net PPE	-11.1%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00
Goodwill	-2.2%	6.00	6.00	5.00	6.00	6.00	6.00	5.00	6.00	6.00	-	-	-	-	-	-	-	-	-	-	-	-
Liabilities	-5.9%	15.00	16.00	18.00	18.00	17.00	17.00	18.00	18.00	21.00	5.00	5.00	4.00	2.00	3.00	3.00	4.00	3.00	6.00	6.00	4.00	4.00
Current Liabilities	-10.8%	6.00	7.00	9.00	9.00	9.00	7.00	12.00	12.00	11.00	4.00	3.00	2.00	2.00	3.00	3.00	3.00	3.00	5.00	6.00	4.00	3.00
Shareholder's Equity	-15.1%	31.00	37.00	41.00	45.00	48.00	52.00	56.00	62.00	68.00	65.00	71.00	74.00	77.00	-	-	-	-	2.00	2.00	7.00	11.00
Retained Earnings	-1.7%	-314	-309	-303	-300	-295	-290	-284	-280	-275	-271	-266	-262	-259	-248	-244	-242	-238	-235	-232	-227	-223
Additional Paid-In Capital	0.0%	347	347	346	346	344	344	344	344	343	337	339	339	339	241	236	235	234	233	232	232	232
Shares Outstanding	0%	17.00	17.00	17.00	17.00	15.00	15.00	16.00	16.00	14.00	13.00	12.00	13.00	9.00	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-2.77	-2.77	-2.77	-2.77	-2.75	-2.88	-2.88	-2.88	-2.84	-2.85	-2.87
Float	-	-	-	-	16,791,123	-	-	-	33.00	-	-	-	79.00	-	-	-	8.00	-	-	-	9.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	25.4%	-4,881	-6,541	-2,953	-3,892	-5,610	-5,368	-4,456	-4,356	-4,902	-4,810	-2,156	-2,596	-3,328	-3,132	-2,050	-2,026	-4,960	-3,605	-3,062	-2,982	-4,224
Share Based Compensation	10.3%	160	145	135	146	126	129	121	113	112	111	102	102	101	99.00	82.00	86.00	83.00	94.00	91.00	91.00	64.00
Cashflow From Investing	100.0%	-	-56.00	-129	-9.00	-8.00	-91.00	-11.00	-14.00	-4,280	-	-	-	-14.00	-5.00	-4.00	-	-	-	-	-	-
Cashflow From Financing	100.0%	-	-1,457	1.00	2,136	-55.00	-3,288	2,734	-	-1,376	-	-	-	74,002	3,359	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SYN Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating Costs and Expenses:
General and administrative	$ 1,933	$ 2,201
Research and development	3,459	2,977
Total Operating Costs and Expenses	5,392	5,178
Loss from Operations	(5,392)	(5,178)
Other Income:
Foreign currency exchange (loss) gain	(1)	6
Interest income	228	364
Total Other Income	227	370
Net Loss before income taxes	(5,165)	(4,808)
Income tax benefit		330
Net Loss Attributable to Common Stockholders	$ (5,165)	$ (4,478)
Net Loss Per Share - Basic (in dollars per share)	$ (0.30)	$ (0.30)
Net Loss Per Share - Dilutive (in dollars per share)	$ (0.30)	$ (0.30)
Weighted average number of shares outstanding during the period - Basic (in shares)	17,148,049	15,124,061
Weighted average number of shares outstanding during the period - dilutive (in shares)	17,148,049	15,124,061
Net Loss	$ (5,165)	$ (4,478)
(Loss) gain (loss) on foreign currency translation	(569)	374
Total comprehensive loss	$ (5,734)	$ (4,104)

SYN Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current Assets
Cash and cash equivalents	$ 18,261,000	$ 23,177,000
Tax credit receivable	1,772,000	1,812,000
Prepaid expenses and other current assets	1,623,000	2,414,000
Total Current Assets	21,656,000	27,403,000
Non-Current Assets
Property and equipment, net	375,000	422,000
Restricted cash	99,000	102,000
Right of use asset	1,634,000	1,759,000
In-process research and development	19,316,000	19,755,000
Goodwill	5,573,000	5,700,000
Deposits and other assets	77,000	78,000
Total Assets	48,730,000	55,219,000
Current Liabilities:
Accounts payable	571,000	770,000
Accrued expenses	3,327,000	2,995,000
Accrued employee benefits	665,000	1,517,000
Deferred research and development tax credit-current portion	886,000	906,000
Loans payable-current	62,000	63,000
Operating lease liability-current portion	498,000	487,000
Total Current Liabilities	6,009,000	6,738,000
Non-current Liabilities
Non-current contingent consideration	6,476,000	6,274,000
Loan Payable - non-current	159,000	162,000
Non-current deferred research and development tax credit	664,000	906,000
Non-current operating lease liability	1,299,000	1,442,000
Total Liabilities	14,607,000	15,522,000
Commitments and Contingencies (Note 13)
Stockholders' Equity:
Common stock, $0.001 par value; 350,000,000 shares authorized, 17,868,282 issued and 17,148,049 outstanding at March 31, 2024 and 17,868,282 issued and 17,148,049 outstanding at December 31, 2023	18,000	18,000
Additional paid-in capital	346,679,000	346,519,000
Treasury stock at cost, 720,233 shares at March 31, 2024 and at December 31, 2023	(288,000)	(288,000)
Accumulated other comprehensive (loss) income	(537,000)	32,000
Accumulated deficit	(314,483,000)	(309,318,000)
Total Stockholders' Equity	31,389,000	36,963,000
Total Liabilities and Stockholders' Equity	48,730,000	55,219,000
Series C convertible preferred stock
Temporary Equity
Convertible preferred stock	2,006,000	2,006,000
Series D convertible preferred stock
Temporary Equity
Convertible preferred stock	$ 728,000	$ 728,000

About Synthetic Biologics Inc

0

WEBSITE	syntheticbiologics.com

Synthetic Biologics Inc Frequently Asked Questions

What is the ticker symbol for Synthetic Biologics Inc? What does SYN stand for in stocks?

SYN is the stock ticker symbol of Synthetic Biologics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Synthetic Biologics Inc (SYN)?

As of Fri May 17 2024, market cap of Synthetic Biologics Inc is 6.57 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SYN stock?

You can check SYN's fair value in chart for subscribers.

What is the fair value of SYN stock?

You can check SYN's fair value in chart for subscribers. The fair value of Synthetic Biologics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Synthetic Biologics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SYN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Synthetic Biologics Inc a good stock to buy?

The fair value guage provides a quick view whether SYN is over valued or under valued. Whether Synthetic Biologics Inc is cheap or expensive depends on the assumptions which impact Synthetic Biologics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SYN.

What is Synthetic Biologics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, SYN's PE ratio (Price to Earnings) is -0.36 and Price to Sales (PS) ratio is 2.78. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SYN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Synthetic Biologics Inc's stock?

In the past 10 years, Synthetic Biologics Inc has provided -0.51 (multiply by 100 for percentage) rate of return.